Sierra Oncology, Inc. (SRRA) [Rocket]

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14
	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Revenues	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0
Revenue growth	-100.0%
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0
Gross margin		100.0%
Selling, general and administrative [+]	27.4	20.1	13.7	14.3	12.5	14.2	9.5	3.5
General and administrative	27.4	20.1	13.7	14.3	12.5	14.2	9.5	3.5
Research and development	67.2	45.1	53.2	41.1	30.2	33.9	26.4	19.1
EBITDA [+]	-94.3	-64.7	-66.9	-55.3	-42.4	-47.9	-35.7	-22.6
EBITDA growth	45.7%	-3.3%	21.0%	30.6%	-11.5%	34.0%	58.3%	463.6%
EBITDA margin		-21567.7%
Depreciation and amortization	0.3	0.2	0.1	0.1	0.3	0.2	0.1	0.0
EBIT [+]	-94.6	-64.9	-67.0	-55.4	-42.6	-48.1	-35.8	-22.6
EBIT growth	45.6%	-3.1%	20.9%	30.0%	-11.3%	34.2%	58.7%	463.7%
EBIT margin		-21647.0%
Other income (expense), net [+]	-0.1	-15.8	-21.4	1.8	0.8	0.4	-17.4	-1.3
Change in fair value of warrants		16.2	20.9				-17.4	-1.4
Other	-0.1	0.4	-0.5	1.8	0.8	0.4	0.1	0.1
Pre-tax income	-94.7	-80.8	-88.4	-53.6	-41.9	-47.7	-53.2	-23.9
Income taxes	0.0	0.1	-0.2	-0.3	0.2	0.1	0.1	0.0
Tax rate	0.0%		0.2%	0.6%
Net income	-94.7	-80.9	-88.3	-53.3	-42.0	-47.9	-453.2	-73.7
Net margin		-26967.3%

Basic EPS [+]	($7.14)	($7.70)	($30.30)	($30.16)	($33.68)	($1.58)	($31.47)	($69.08)
Growth	-7.2%	-74.6%	0.5%	-10.5%	2027.7%	-95.0%	-54.4%	260.1%
Diluted EPS [+]	($7.14)	($7.70)	($30.30)	($30.16)	($33.68)	($1.58)	($31.47)	($69.08)
Growth	-7.2%	-74.6%	0.5%	-10.5%	2027.7%	-95.0%	-54.4%	260.1%

Shares outstanding (basic) [+]	13.3	10.5	2.9	1.8	1.2	30.2	14.4	1.1
Growth	26.1%	260.6%	64.7%	41.8%	-95.9%	110.0%	1249.2%	63.2%
Shares outstanding (diluted) [+]	13.3	10.5	2.9	1.8	1.2	30.2	14.4	1.1
Growth	26.1%	260.6%	64.7%	41.8%	-95.9%	110.0%	1249.2%	63.2%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.